CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

baloxavir marboxil

Last Updated: November 12, 2020
Result type: Reports
Product Line: Reimbursement Review

Generic Name: baloxavir marboxil

Brand Name: Xofluza

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Influenza

Indications: Treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza complications.

Submission Type: Non-submission

Project Status: Not filed

Recommendation Type: CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer